Novel Research LLC

Running trials

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Source

• Recruiting

  PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

  NCT07611214· Phase 4· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Source

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Source

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT06475742· Phase 3· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Source

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· Phase 3· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)3 recruiting
• Sjögren's disease3 recruiting
• Crohn's disease2 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

  NCT05369832· Phase 4· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Source